VivoSim Labs (VIVS)

VivoSim’s therapeutic focus includes FXR314, a program being developed for inflammatory bowel disease, including ulcerative colitis. FXR, or farnesoid X receptor, is involved in biological pathways linked to gastrointestinal and liver function, making it a target of interest in diseases where inflammation, metabolism, and tissue health overlap. The company’s rationale for FXR314 is supported by preclinical work and evidence generated in 3D human tissue systems.

Alongside its internal development efforts, VivoSim provides research and predictive screening services to pharmaceutical and biotechnology companies. These services include liver toxicology testing intended to identify safety issues earlier in the drug development process. The company also works on models that can help assess intestinal side-effect profiles, which is important for therapeutic candidates across multiple stages of discovery and development.

VivoSim’s distinctive feature is the combination of a services platform and a targeted drug-development pipeline. By applying human tissue-based systems to both external customer work and internal programs, the company aims to improve translational insight compared with traditional preclinical approaches. Investors generally assess VivoSim by considering the progress of FXR314, demand for its screening services, scientific validation, and the funding required to advance biotechnology programs.